He, Zhiyong

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., et al. (2021) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 483

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Ma, R., et al. (2020) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 390

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial

HARMONi-A Study Investigators, Fang, W., Zhao, Y., Luo, Y., Yang, R., Huang, Y., He, Z., Zhao, H., Li, M., Li, K., et al. (2026) · JAMA

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 8